Jeremy Cetnar is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 95 publications with 2,871 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Mail Code Cr 145
Portland, OR 972393011
Telephone
503-494-6346Registry record last updated 26 Sept 2013.
Clinical trials
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Sponsor: National Cancer Institute (NCI)
- Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Sponsor: Adamis Pharmaceuticals Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
- Merck Sharp & Dohme LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.1%Kinase inhibitor24.7%Tagrisso40%Alecensa28%Gavreto17%Mekinist15%Part D<11 patientsOther protein kinase inhibitors4.8%Rozlytrek100%Part D<11 patients+ 2 more classes in this area
Nervous system
20.6%Opioid Agonist15.1%Oxycodone Hcl71%Morphine Sulfate Er30%Part D<11 patientsPhenothiazine5.5%Prochlorperazine Maleate100%Part D≥14 patientsSensory organs
18.6%Corticosteroid18.6%Dexamethasone54%Hydrocortisone46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
Proceedings of the National Academy of Sciences
2026 - Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report
JTO Clinical and Research Reports
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”